• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prime Medicine Inc (NQ: PRME )

4.030 +0.150 (+3.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prime Medicine Inc

< Previous 1 2 Next >
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
October 24, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
October 15, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Unveils Strategically Focused Pipeline
September 30, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
September 30, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
August 28, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
May 30, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 13, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
May 08, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
May 01, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
April 29, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
April 23, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
February 28, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 20, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Pricing of Upsized Public Offering
February 14, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Proposed Public Offering of Common Stock
February 14, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
January 25, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
2 gene editing stocks to keep on your 2024 watchlist
January 23, 2024
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
January 05, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
November 08, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 03, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
October 27, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
October 24, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
October 17, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
September 19, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
August 31, 2023
From Prime Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap